Dr. James Orbinski Joins Onco-Innovations' Scientific and Clinical Advisory Board to Bolster Company's Mission
Rhea-AI Summary
Onco-Innovations (OTCQB:ONNVF) has announced the appointment of Dr. James Orbinski to its Scientific and Clinical Advisory Board. Dr. Orbinski, a former International President of Médecins Sans Frontières (MSF), is notable for accepting the Nobel Peace Prize on behalf of MSF in 1999.
Currently a Full Professor at Temerty School of Medicine and the University of Toronto, Dr. Orbinski brings extensive experience in global health and humanitarian medicine. He was the founding Director of the Dahdaleh Institute for Global Health Research and co-chaired MSF's Neglected Diseases Working Group. His work with the Drugs for Neglected Diseases Initiative (DNDi) has led to the development of 13 treatments for 6 deadly diseases since 2003.
An Officer of the Order of Canada and recipient of the Meritorious Service Cross, Dr. Orbinski will provide strategic insight for Onco's scientific programs and global oncology innovations.
Positive
- Addition of highly credentialed advisor with Nobel Peace Prize association
- Strategic expertise in global health systems and medical innovation
- Proven track record in developing treatments through DNDi (13 treatments for 6 diseases)
Negative
- None.
News Market Reaction – ONNVF
In the trading session that priced this news, ONNVF declined 31.77%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, BC / ACCESS Newswire / April 22, 2025 / Onco-Innovations Limited(CSE:ONCO)(OTCQB:ONNVF) (Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce the appointment of Dr. James Orbinski as a member of the Company's Scientific and Clinical Advisory Board.
A former International President of Médecins Sans Frontières/Doctors Without Borders (MSF), Dr. Orbinski accepted the Nobel Peace Prize on behalf of MSF in 1999. He has provided medical humanitarian relief in complex emergencies including war, famine, epidemic disease, and genocide, and has held leadership roles in some of the world's most impactful global health initiatives.[1]
With his extensive background in global health, humanitarian medicine, and health systems leadership, Dr. Orbinski is expected to provide strategic insight and guidance as the Company advances its scientific programs and explores opportunities to expand the global impact of its oncology innovations.
Dr. Orbinski is currently Full Professor at Temerty School of Medicine, and at the Munk School of Global Affairs & Public Policy and the Dalla Lana School of Public Health at the University of Toronto.[2] He was the founding Director of the Dahdaleh Institute for Global Health Research at York University, which focused on use of disease modelling and AI for COVID in Africa and for clinical public health priority setting globally, and on modelling the health impacts of climate change. [3] He co-chaired the MSF Neglected Diseases Working Group, and its Drugs for Neglected Diseases Initiative (DNDi), a globally successful product development partnership focused on medicines and health care technologies for neglected diseases of the Global South. Since 2003, the DNDi has developed 13 treatments for 6 deadly diseases. He also co-founded Dignitas International, a hybrid academic NGO focused on clinical and health systems research for community based clinical care for people with HIV and TB in the Global South. He was a member of the Program Advisory Council, for Grand Challenges Canada, and its Chair of the Humanitarian Grand Challenges Sub-Committee. In addition, he was the subject of the award-winning feature documentary "Triage: Dr. James Orbinski's Humanitarian Dilemma", which explores the moral and ethical challenges of humanitarian medicine.
He is the best-selling author of An Imperfect Offering: Humanitarianism in the Twenty-First Century, an award-winning book that examines the political and ethical realities of providing care in the world's most challenging crisis zones. [4]
Dr. Orbinski has served on the boards and advisory councils of numerous organizations dedicated to improving health outcomes and access to essential medicines. His work has helped launch new treatments for neglected tropical diseases and strengthen healthcare delivery in underserved communities globally, including work with Indigenous communities in Canada.[5]
Dr. Orbinski is an Officer of the Order of Canada and a recipient of the Meritorious Service Cross for his medical work during the 1994 Rwandan genocide. He holds a BSc from Trent University, an MD from McMaster University, and an MA in International Relations from the University of Toronto.[6]
"We are honoured to welcome Dr. Orbinski to Onco-Innovations. His unparalleled experience in global health, humanitarian medicine, and health systems innovation brings a unique and invaluable perspective to our work. Dr. Orbinski's lifelong commitment to equity and transformative health solutions aligns deeply with our mission to pioneer breakthroughs in cancer care and improve outcomes for patients around the world," stated Thomas O'Shaughnessy, CEO of Onco-Innovations.
About Onco-Innovations Limited
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to prevent and cure cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology that targets solid tumours, setting new standards in cancer treatment. Onco's commitment to excellence and innovation drives it to develop advanced therapies that improve patient outcomes and offer hope in the fight against cancer.
ON BEHALF OF ONCO-INNOVATIONS LIMITED,
"Thomas O'Shaughnessy"
Chief Executive Officer
For more information, please contact:
Thomas O'Shaughnessy
Chief Executive Officer
Tel: + 1 888 261 8055
investors@oncoinnovations.com
The CSE and Information Service Provider have not reviewed and do not accept responsibility for the accuracy or adequacy of this release.
Forward-Looking Statements Caution. This news release contains forward-looking statements relating to the prospects of the Company, and the Company's business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "potential", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
[2] https://munkschool.utoronto.ca/person/james-j-orbinski
[4] https://munkschool.utoronto.ca/person/james-j-orbinski
[6] Ibid
SOURCE: Onco-Innovations Limited
View the original press release on ACCESS Newswire